🚀 VC round data is live in beta, check it out!
ST Pharm Valuation Multiples
Discover revenue and EBITDA valuation multiples for ST Pharm and similar public comparables like Syngene, Fagron, Piramal Pharma, PharmaResearch and more.
ST Pharm Overview
About ST Pharm
St Pharm Co Ltd offers custom manufacturing services of Active pharmaceutical ingredients and their intermediates for their use in pharmaceutical development and be compliant to cGMP, requirements. The firm’s business areas include commercial manufacturing of new drug development, manufacturing of generic active pharmaceutical ingredients, fine chemical’s business and development of oligonucleotide therapeutics. The company’s products comprise small molecule active pharmaceutical ingredients, Anti-cancer, Anti- coagulant active pharmaceutical ingredients, etc.
Founded
2008
HQ
Employees
N/A
Website
Financials (LTM)
EV
$2B
ST Pharm Financials
ST Pharm reported last 12-month revenue of $241M and EBITDA of $61M.
In the same LTM period, ST Pharm generated $98M in gross profit, $61M in EBITDA, and $39M in net income.
Revenue (LTM)
ST Pharm P&L
In the most recent fiscal year, ST Pharm reported revenue of $227M and EBITDA of $63M.
ST Pharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $241M | XXX | $227M | XXX | XXX | XXX |
| Gross Profit | $98M | XXX | $93M | XXX | XXX | XXX |
| Gross Margin | 41% | XXX | 41% | XXX | XXX | XXX |
| EBITDA | $61M | XXX | $63M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 28% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $39M | XXX | $38M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | — | — | $31M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ST Pharm Stock Performance
ST Pharm has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
ST Pharm's stock price is $95.40.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $1.81 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialST Pharm Valuation Multiples
ST Pharm trades at 8.2x EV/Revenue multiple, and 32.3x EV/EBITDA.
EV / Revenue (LTM)
ST Pharm Financial Valuation Multiples
As of April 20, 2026, ST Pharm has market cap of $2B and EV of $2B.
Equity research analysts estimate ST Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ST Pharm has a P/E ratio of 50.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 8.2x | XXX | 8.7x | XXX | XXX | XXX |
| EV/EBITDA | 32.3x | XXX | 31.1x | XXX | XXX | XXX |
| EV/EBIT | 48.3x | XXX | 52.2x | XXX | XXX | XXX |
| EV/Gross Profit | 20.1x | XXX | 21.2x | XXX | XXX | XXX |
| P/E | 50.8x | XXX | 52.6x | XXX | XXX | XXX |
| EV/FCF | 67.5x | XXX | 68.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ST Pharm Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ST Pharm Margins & Growth Rates
ST Pharm's revenue in the last 12 month grew by 20%.
ST Pharm's rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ST Pharm's rule of X is 78% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
ST Pharm Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 46% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 78% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 24% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ST Pharm Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene | XXX | XXX | XXX | XXX | XXX | XXX |
| Fagron | XXX | XXX | XXX | XXX | XXX | XXX |
| Piramal Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| PharmaResearch | XXX | XXX | XXX | XXX | XXX | XXX |
| Granules India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ST Pharm M&A Activity
ST Pharm acquired XXX companies to date.
Last acquisition by ST Pharm was on XXXXXXXX, XXXXX. ST Pharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ST Pharm
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialST Pharm Investment Activity
ST Pharm invested in XXX companies to date.
ST Pharm made its latest investment on XXXXXXXX, XXXXX. ST Pharm invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ST Pharm
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ST Pharm
| When was ST Pharm founded? | ST Pharm was founded in 2008. |
| Where is ST Pharm headquartered? | ST Pharm is headquartered in South Korea. |
| Who is the CEO of ST Pharm? | ST Pharm's CEO is Moo-Je Sung. |
| Is ST Pharm publicly listed? | Yes, ST Pharm is a public company listed on Korea Exchange. |
| What is the stock symbol of ST Pharm? | ST Pharm trades under 237690 ticker. |
| When did ST Pharm go public? | ST Pharm went public in 2016. |
| Who are competitors of ST Pharm? | ST Pharm main competitors are Syngene, Fagron, Piramal Pharma, PharmaResearch. |
| What is the current market cap of ST Pharm? | ST Pharm's current market cap is $2B. |
| What is the current revenue of ST Pharm? | ST Pharm's last 12 months revenue is $241M. |
| What is the current revenue growth of ST Pharm? | ST Pharm revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of ST Pharm? | Current revenue multiple of ST Pharm is 8.2x. |
| Is ST Pharm profitable? | Yes, ST Pharm is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ST Pharm? | ST Pharm's last 12 months EBITDA is $61M. |
| What is ST Pharm's EBITDA margin? | ST Pharm's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of ST Pharm? | Current EBITDA multiple of ST Pharm is 32.3x. |
| What is the current FCF of ST Pharm? | ST Pharm's last 12 months FCF is $29M. |
| What is ST Pharm's FCF margin? | ST Pharm's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of ST Pharm? | Current FCF multiple of ST Pharm is 67.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.